Emerging biopharma faces tougher markets, leaner budgets, and higher expectations. In this session, Scott breaks down key economic and market trends shaping clinical operations—from funding constraints to pipeline reprioritization—and shares practical strategies to navigate these challenges, forge smart partnerships, and maintain operational excellence in an unforgiving landscape.

Amid biotech's ongoing transformation, fueled by tighter capital markets, shifting board expectations, and increasingly complex partnership models, leaders are under pressure to do more with less—and faster. This presentation distills the strategic and operational insights shared throughout the session, spotlighting the critical takeaways every clinical leader should walk away with. From investor-driven execution metrics to the ripple effects of M&A and IPO events on trial continuity, we'll explore how small and mid-sized biotechs can stay agile while maintaining quality. We'll also briefly address the role of "one BBB", tariffs, and their influence on acquisition preparedness and operational predictability.

Risk-based monitoring (RBM) has evolved from a resource optimization strategy into a powerful compliance tool that can predict and prevent FDA inspection findings before they occur. This presentation demonstrates how organizations can transform their RBM programs into proactive early warning systems that detect regulatory vulnerabilities in real-time. 

Drawing on FDA inspection trends and common 483 observations, we explore how strategic risk indicators—including consent process deviations, data integrity issues, protocol non-compliance, and safety reporting delays—can be systematically monitored through centralized and onsite activities. Attendees will learn how to design risk thresholds and triggers that align with FDA expectations, enabling study teams to identify compliance gaps before they escalate into formal findings. 

The presentation provides a practical framework for translating RBM signals into effective mitigation strategies, targeted corrective actions, and preventive measures that strengthen overall trial quality. Real-world case examples illustrate how early detection through RBM has enabled sponsors to address potential findings proactively, resulting in cleaner inspections and improved regulatory outcomes. 

Participants will leave equipped to enhance their monitoring programs to serve dual purposes: optimizing operational efficiency while safeguarding regulatory compliance.

Clinical trials are entering a new era—one defined not by automation alone, but by the integration of Agentic AI into daily operations. This session features a real-world case study showcasing how AI teammates are transforming clinical development from manual coordination to intelligent, self-driving systems that adapt, learn, and act across study activities. Attendees will explore where Agentic AI creates the greatest impact, gain practical insights into implementation and validation, and learn how to navigate key adoption challenges in this rapidly evolving field. Join us to see what’s working today and how to prepare for tomorrow’s AI-driven clinical operations.

Attendees will gain a clear understanding of how Agentic AI and advanced data analytics can transform clinical trials from static, protocol-driven processes into adaptive, precision-focused frameworks. They will learn practical approaches for integrating AI-driven insights into trial design, patient recruitment, and operational decision-making. The session will also highlight real-world examples, emerging best practices, and future trends that can help organizations accelerate innovation and improve patient-centric outcomes.

Clinical trials are complex enough—operational challenges, competing processes, and communication gaps between Sponsor and CRO can turn complex into chaos. In this candid session, we'll walk through the real story of an Alzheimer’s Disease clinical trial that encountered significant hurdles early on due to evolving Sponsor–CRO dynamics, decentralized leadership, vendor performance issues, and pandemic-era disruptions. During this fireside chat, we’ll explore how a change in leadership at the Sponsor, a renewed focus on the patient, and a commitment to partnership transformed the trajectory of the trial and turned breakdowns into breakthroughs. Through open bi-directional dialogue, cross-organizational accountability, and a shared North Star, the Sponsor and CRO teams were able to realign and deliver on critical milestones despite the rough start and persistent sub-optimal performance from vendor partners. This session will offer practical, hard-earned lessons for Sponsors and CROs alike on how to lead teams through broken relationships and establish high-functioning partnerships built on trust, transparency, and shared purpose.

The hybrid approach might be right for you! As a small biopharma/biotech we might be enticed to hand off all of the work to an outsourcing partner, but I encourage you to think differently. Can you, with compliance in mind, take on this work internally? You can build an operational team that can—and will—deliver. I will share three or four success stories over the last 10 years.

CBP will provide an overview of major U.S. regulatory authorities governing biological material importations, guidelines for acceptable and unacceptable cargo descriptions, examples of non-compliant shipments of biological materials and pharmaceutical products, and provide essential resources and important contacts for support.

The presentation outlines the role of the Pharmaceutical, Health, and Chemicals Center of Excellence and Expertise (PHC CEE) within CBP. It details the center’s structure, industry collaboration, enforcement responsibilities, and classification guidance for various pharmaceutical, healthcare, and chemical imports. It also highlights coordination with other government agencies and provides resources for compliance and trade facilitation.

Monitoring temperature control is a vital responsibility in clinical supply, extending beyond deep-frozen storage. Even products stored at ambient conditions require monitoring to ensure they avoid freezing or overheating. This session explains how tracking at defined supply chain touchpoints enables data collection, trending, and timely intervention. By leveraging value stream checkpoints, organizations can proactively maintain product integrity, safeguarding quality while minimizing risks across distribution and storage environments.

In fully outsourced trials, sponsor-site relationships might seem secondary—but for small and emerging biopharmas, they can be a key differentiator. Even when using a CRO or FSP model, sites still look to sponsors for clarity, support, and partnership. This session will explore why direct sponsor-site engagement still matters, how it impacts trial success, and practical ways to build trust and alignment—regardless of your outsourcing structure.